Orthofix will conduct clinical studies, work to acquire regulatory approvals and commercialize Novosis’ recombinant human bone morphogenetic protein-2 technology in the U.S. and Canada, according to an Aug. 2 news release.
Novosis is a bone graft material made of a synthetic carrier and rhBMP-2. It acts as a scaffold for the formation of new bone. About 50,000 patients have received the bone graft.
“Pending successful U.S. clinical trials and subsequent approvals, this surgeon-driven biologic solution will provide a moldable, flowable, bioactive rhBMP-2 bone graft material in the U.S. and fits well within our comprehensive portfolio of allografts with viable cells, demineralized fiber allografts, DBMs, synthetic scaffolds and spinal constructs,” Orthofix President and CEO Jon Serbousek said in the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
